Key Developments: BTG PLC (BTG.L)

BTG.L on London Stock Exchange

662.00GBp
19 Sep 2014
Price Change (% chg)

4.50p (+0.68%)
Prev Close
657.50p
Open
668.00p
Day's High
671.00p
Day's Low
659.00p
Volume
791,446
Avg. Vol
444,265
52-wk High
671.10p
52-wk Low
365.30p

Search Stocks

Latest Key Developments (Source: Significant Developments)

SciClone Pharmaceuticals Inc and BTG announce that DC Bead has been approved by China Food and Drug Administration
Thursday, 28 Aug 2014 02:00am EDT 

SciClone Pharmaceuticals Inc:Announced that China Food and Drug Administration has approved registration of DC Bead for embolization of malignant hypervascularized tumors.BTG and SciClone previously entered into an agreement granting SciClone exclusive licensing and distribution rights to DC Bead in China.Under agreement, SciClone will purchase product from BTG at specified price for sale in China.Commercial launch plans are underway.  Full Article

BTG PLC reaffirms FY 2015 revenue guidance
Wednesday, 16 Jul 2014 02:00am EDT 

BTG PLC:Expects FY 2015 revenue to be in 330-345 mln pounds range as previously guided, despite recent weakening of the US dollar versus sterling.FY 2015 revenue of 342 mln pounds - Thomson Reuters I/B/E/S.  Full Article

BTG Plc's EKOS initiates pivotal new study in patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome
Wednesday, 11 Jun 2014 08:00am EDT 

EKOS Corporation:Start of patient enrollment for ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOSSystem ( ACCESS PTS ) Study.Deep Vein Thrombosis (DVT) is a common medical condition affecting 600,000 people annually in the United States.Says most common complication of DVT is Post-Thrombotic Syndrome (PTS), which can affect from 25 pct to 60 pct of individuals suffering DVT.Despite traditional anticoagulation and elastic compression stocking therapy, a significant proportion of DVT becomes chronic with post-thrombotic sequelae which impose significant limitations to a patient's quality of life.ACCESS PTS study is a prospective, single-arm, multi-center trial, designed to evaluate the safety and efficacy of ultrasound accelerated thrombolysis using the EkoSonicEndovascular System with standard infusion of thrombolytic drug for PTS and chronic venous occlusions.Study will enroll up to 200 subjects over a period of 12 months at about 30 study sites across the United States.Subjects will receive clinical follow-up for 12 months.EKOS Corporation is asubsidiary of BTG plc.  Full Article

BTG PLC announces EkoSonic Endovascular System receives FDA Clearance for treatment of pulmonary embolism in USA
Friday, 23 May 2014 02:02am EDT 

BTG PLC:EKOS Corp, BTG International group company announced US FDA has cleared EkoSonic Endovascular System.EkoSonic Endovascular system for ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into vasculature for treatment of pulmonary embolism.EKOS ultrasonic devices are designed to gently accelerate penetration of thrombolytic agents into thrombus, providing high levels of lysis.EKOS is only minimally invasive endovascular therapy on market that has been FDA cleared for treatment of PE.  Full Article

BTG plc gives FY 2015 revenue guidance in line with analysts' estimates - Conference Call
Tuesday, 20 May 2014 04:30am EDT 

BTG plc:Sees revenue guidance of between 330 million pounds to 345 million pounds for FY 2015.FY 2015 revenue of 343 million pounds - Thomson Reuters I/B/E/S.  Full Article

BTG Sees FY 2014 revenue guidance around top end of prior range
Thursday, 3 Apr 2014 02:00am EDT 

BTG Plc:Expects to be around the top end of the revenue guidance range of 275-285 mln pounds for FY 2014.  Full Article

BTG Plc reaffirms FY 2014 revenue guidance
Wednesday, 29 Jan 2014 02:00am EST 

BTG Plc:Says for FY 2014 it reiterates its guidance of revenue in the range 275 million pounds to 285 million pound.FY 2014 revenues of 285 million pounds - Thomson Reuters I/B/E/S Estimates.  Full Article

FDA approves BTG Plc's Varithena for treatment of patients
Tuesday, 26 Nov 2013 05:44am EST 

BTG Plc:Says the US Food and Drug Administration (FDA) has approved Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.  Full Article

BTG Plc Reaffirms FY 2014 Revenue Guidance
Tuesday, 12 Nov 2013 02:00am EST 

BTG Plc announced that it on track to deliver revenue of GBP275 million to GBP285 million for fiscal 2014. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of GBP281 million for fiscal 2014.  Full Article

BTG Plc Raises FY 2014 Revenue Guidance
Thursday, 3 Oct 2013 02:00am EDT 

BTG Plc announced that for fiscal 2014, it increased its revenue guidance from a range of GBP235 million-GBP245 million to GBP275 million-GBP285 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of GBP280 million for fiscal 2014.  Full Article

BRIEF-BTG receives FDA nod for pulmonary embolism treatment

* Ekosonic endovascular system receives FDA clearance for treatment of pulmonary embolism in USA Source text for Eikon: Further company coverage:

Search Stocks